Straits Times Index
3,203.82 -14.35 (-0.45%) S&P 500
4,576.22 +24.54 (+0.54%) Dow
35,623.65 +132.96 (+0.37%) Nasdaq
15,345.04 +109.20 (+0.72%) BTC-USD
61,510.84 +2,555.04 (+4.33%) CMC Crypto 200
1,482.52 +63.14 (+4.45%)
Lonza Group Ltd (LZAGY)
| Previous close | 82.10 |
| Open | 83.05 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 82.74 - 83.08 |
| 52-week range | 55.69 - 86.31 |
| Volume | 839 |
| Avg. volume | 50,621 |
| Market cap | 61.462B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 79.92 |
| EPS (TTM) | 1.04 |
| Earnings date | N/A |
| Forward dividend & yield | 0.33 (0.40%) |
| Ex-dividend date | 10 May 2021 |
| 1y target est | N/A |
- Investing.com
Moderna Slips As Issues At Partners Delay Overseas Release Of Shots
By Dhirendra Tripathi
- Reuters
Vaccine business helps Lonza lift 2021 sales outlook
ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.
- Zacks
Lonza Group Ag (LZAGY) Upgraded to Buy: What Does It Mean for the Stock?
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
